Verve Enterprise Value Over E B I T D A from 2010 to 2025
| VERV Stock | USD 6.31 0.14 2.17% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (3.16) | Current Value (3.31) | Quarterly Volatility 52.2816214 |
Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 25.8 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 83.12, Dividend Yield of 0.0 or PTB Ratio of 1.41. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.
Verve | Enterprise Value Over E B I T D A |
Latest Verve Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Verve Therapeutics over the last few years. It is Verve Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Verve Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Verve Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (77.45) | |
| Geometric Mean | 41.77 | |
| Coefficient Of Variation | (67.50) | |
| Mean Deviation | 48.28 | |
| Median | (116.07) | |
| Standard Deviation | 52.28 | |
| Sample Variance | 2,733 | |
| Range | 113 | |
| R-Value | 0.86 | |
| Mean Square Error | 759.11 | |
| R-Squared | 0.74 | |
| Significance | 0.000019 | |
| Slope | 9.45 | |
| Total Sum of Squares | 41,001 |
Verve Enterprise Value Over E B I T D A History
About Verve Therapeutics Financial Statements
Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (3.16) | (3.31) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.